Edition No. 48 · GlobalEst. 2026
PLANET EARTH NEWS
Network

30 days left in your free trial. Subscribe now — just $10/month.

S&P 5007,706.03+2.04%Dow Jones51,511.59+0.10%Nasdaq26,936.04+3.69%FTSE 10010,705.26+0.16%DAX25,410.63-0.50%Nikkei 22565,746.62+3.56%Hang Seng24,716.24+0.46%EUR/USD1.1390-0.75%GBP/USD1.3246-0.84%Gold4,315.70-1.56%Crude Oil92.15-3.79%Bitcoin84,073.39+3.61%S&P 5007,706.03+2.04%Dow Jones51,511.59+0.10%Nasdaq26,936.04+3.69%FTSE 10010,705.26+0.16%DAX25,410.63-0.50%Nikkei 22565,746.62+3.56%Hang Seng24,716.24+0.46%EUR/USD1.1390-0.75%GBP/USD1.3246-0.84%Gold4,315.70-1.56%Crude Oil92.15-3.79%Bitcoin84,073.39+3.61%

AI-Powered Screening Platform Improves Efficiency in Retina Clinical Trials

New technology helps medical researchers identify eligible patients faster, reducing screen failures and increasing trial participation.

Par Planet Earth News Medicine Desk· Publié 2026-09-23· 2 min read
PENN Explainer

Hear this story explained in 90 seconds.

A new artificial intelligence platform is changing how medical professionals conduct clinical trials for eye diseases. Researchers recently presented findings at the American Society of Retina Specialists 2026 annual meeting, known as ASRS 2026, regarding a tool designed to streamline patient recruitment. The study focused on how AI can assist in identifying candidates for complex retina research. Manual screening for these trials is often a labor-intensive process for medical staff. According to Louie Cai, a doctor who helped lead the research, reviewing patient charts and imaging can take up to an hour for each individual patient. This time-consuming task often leads to delays in starting important medical studies. The new AI platform was developed to automate this process by checking patient documentation against specific trial eligibility criteria in real time. By analyzing data quickly, the system helps doctors determine if a patient is a good fit for a study without the need for extensive manual review. The researchers tested the platform within a retina practice to see if it could improve overall efficiency. The results showed that the use of this AI tool increased the rate of patient randomization by 37.5 percent. Additionally, the system helped reduce the number of screen failures by 13 percent. A screen failure occurs when a patient is considered for a trial but is later found to be ineligible, which wastes valuable time and resources. By catching these issues earlier, the platform allows medical teams to focus their efforts on patients who are most likely to qualify. This development is seen as a significant step forward in making clinical research more accessible and efficient. As medical technology continues to evolve, tools like this AI platform may play a larger role in accelerating the discovery of new treatments. The ability to conduct trials more effectively could lead to faster breakthroughs in eye care and other medical fields. Future studies will likely explore how this technology can be applied across different types of medical practices and research environments.
Ask the Author

Subscribers can ask the journalist a question about this story. Subscribe to ask.

Note de neutralité

Auto-harvested from global news wires and presented neutrally by PENN.

Share this article

to vote

Comments

No comments yet — be the first to share your thoughts.

Related stories in Medicine